10-Q: Healthcare Triangle Reports Q3 2026 Results, Revenue Surges 161%

Healthcare Triangle, Inc. (HCTI) reported a substantial 161% year-over-year revenue increase for Q3 2026, driven by its Customer Engagement Services segment, but also disclosed a widening net loss and ongoing Nasdaq listing concerns.

Summary

• Healthcare Triangle, Inc. (HCTI) reported Q3 2026 revenue of $9.12 million, a 161% increase from $3.49 million in Q3 2025, primarily due to the Customer Engagement Services segment acquired in January 2026.
• The company incurred a net loss of $2.53 million for Q3 2026, compared to a net loss of $1.91 million in the prior year's quarter.
• For the nine months ended September 30, 2026, revenue was $28.16 million, up 162% from $10.75 million in the same period last year, while the net loss increased to $13.15 million from $4.97 million.
• The company's cash and cash equivalents decreased to $1.87 million as of September 30, 2026, from $7.63 million as of December 31, 2025.
• HCTI received a Staff Delisting Determination from Nasdaq on October 1, 2026, due to noncompliance with the minimum bid price requirement, and is awaiting a decision from the Nasdaq Hearings Panel after appealing the determination.
• Subsequent to the quarter, HCTI completed a one-for-twenty reverse stock split on October 26, 2026, as part of its efforts to regain compliance with Nasdaq's minimum bid price.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant net losses, increased operating expenses, and ongoing challenges with Nasdaq listing compliance, despite revenue growth.

Positives

• Significant revenue growth of 161% year-over-year for the third quarter, reaching $9.12 million, driven by the acquisition of the Customer Engagement Services segment.
• Overall revenue for the first nine months of 2026 increased by 162% to $28.16 million.
• Gross margin improved to 23% in Q3 2026 from 18% in Q3 2025, with the Customer Engagement Services segment achieving a 28% gross margin.
• The company has access to an Equity Line of Credit (up to $50,000) and an At-the-Market Sales Agreement to fund operations.
• The company is pursuing a separation of its Teyame AI Holdings Inc. subsidiary, which may unlock value for stockholders.

Negatives

• Net loss widened to $2.53 million in Q3 2026 from $1.91 million in Q3 2025, and the nine-month net loss increased to $13.15 million from $4.97 million.
• Operating expenses increased significantly, with cost of revenue up 145% and sales and marketing up 50% in Q3 2026.
• Cash and cash equivalents decreased substantially to $1.87 million from $7.63 million.
• The company received a Staff Delisting Determination from Nasdaq and is at risk of delisting.
• Current liabilities ($14.38 million) exceeded current assets ($8.86 million) as of September 30, 2026, resulting in a current ratio of 0.62.

Risks

• Potential delisting from The Nasdaq Stock Market LLC due to noncompliance with minimum bid price requirements.
• The company's ability to continue as a going concern is dependent on its ability to access capital through its Equity Line of Credit and At-the-Market Sales Agreement, which are subject to market conditions and Nasdaq listing status.
• Significant increase in operating expenses, particularly cost of revenue and sales and marketing, impacting profitability.
• The company has a substantial level of indebtedness and contingent consideration, which could adversely affect its financial condition.
• The acquisition of Teyame and Datono is critical for future growth, and successful integration is essential but carries inherent risks.
• Dependence on a few major customers, with the top five accounting for 58% of Q3 2026 revenue.

Future Outlook

The company expects its future research and development expenses to increase in absolute dollars, although it may vary as a percentage of revenue. Sales and marketing expenses are also expected to increase in absolute dollar terms to support business expansion. General and administrative expenses are expected to continue increasing to support business growth, with a long-term expectation of decreasing as a percentage of revenue. Depreciation and amortization expenses are expected to increase due to ongoing investments and acquisitions. The company believes its existing cash, along with funds from its At-the-Market Sales Agreement and Equity Line of Credit, will be sufficient to meet working capital requirements for the next 12 months.

Management Comments

• Management concluded that the company has sufficient resources to fund operations and meet its obligations for at least the next twelve months, citing net assets and the Equity Line of Credit.
• Management expects gross margin to continue increasing as new contracts are negotiated at higher margins.
• Management believes the acquisition of Teyame and Datono will accelerate innovation and strengthen the company's position in the healthcare AI market.
• Management expects the integration of Teyame's AI capabilities with HCTI's infrastructure to create cross-functional synergies.

Industry Context

StockSavvy.ai notes that Healthcare Triangle operates in the competitive and rapidly evolving healthcare IT and AI sectors. The significant revenue growth is largely attributed to the recent acquisition of Teyame and Datono, which bolsters its AI and customer engagement capabilities. However, the company faces challenges in managing its increasing operating expenses and maintaining profitability, a common hurdle for growth-stage technology companies, especially those undergoing significant M&A activity.

Comparison to Industry Standards

• The company's revenue growth of 161% in Q3 2026 significantly outpaces the typical growth rates seen in many mature IT services sectors, but is more aligned with high-growth technology companies, particularly those in AI and customer engagement solutions.
• The gross margin of 23% is within the range for IT services companies, but the company aims for further improvement, suggesting it may be below the higher end of industry benchmarks for highly specialized or software-centric businesses.
• The net loss position is a concern. While many growth-stage tech companies operate at a loss while investing heavily, the increasing net loss alongside revenue growth indicates significant operational costs and integration expenses, which need careful management to align with industry best practices for sustainable growth.
• The company's reliance on a few large customers (58% of Q3 revenue) is a common characteristic in B2B IT services, but industry best practice often encourages diversification to mitigate risk.

Legal Proceedings

• L1 Capital Global Opportunities Master Fund Ltd filed proceedings in the Cayman Islands seeking declarations regarding the adjustment of its warrant exercise price and issuable shares. The company is taking legal advice.

Related Party Transactions

• Services received and paid for from SecureKloud Technologies Limited, India: $1,225,000 in Q3 2026.
• Amounts advanced to SecureKloud Technologies Limited, India: $0 in Q3 2026, $525,000 in Q3 2025.
• Services received and paid for from Blockedge Technologies, Inc.: $60,000 in Q3 2026.
• Amounts advanced to Blockedge Technologies, Inc.: $140,000 in Q3 2025.
• Remuneration to Key Management Personnel: $309,000 in Q3 2026.
• Compensation to Board of Directors: $55,000 in Q3 2026.
• Issuance of common stock to Blockedge Technologies Inc. and Robinson Vincent (on behalf of SecureKloud Technologies Limited, India) in connection with the extinguishment of Series B Preferred Stock.

Stakeholder Impact

• Shareholders: Potential dilution from ongoing equity financings (ELOC, ATM), risk of delisting from Nasdaq impacting share price and liquidity, but also potential upside from Teyame separation.
• Creditors: The company has significant debt obligations, including convertible notes maturing soon, and its ability to repay depends on continued access to capital.
• Employees: The company is growing its employee base and has stock-based compensation, but the financial performance and Nasdaq delisting risk could impact morale and job security.
• Customers: Continued service delivery is expected, but potential financial instability or delisting could create uncertainty for long-term contracts.

Next Steps

• The company is pursuing a separation of Teyame AI Holdings Inc. and a direct listing of its common stock.
• HCTI is appealing the Nasdaq Staff Delisting Determination and awaiting a decision from the Nasdaq Hearings Panel.
• The company is continuing to implement a strategic realignment of its U.S. operations through Purpose Health Inc.
• The company will continue to utilize its Equity Line of Credit and At-the-Market Sales Agreement for funding, subject to market conditions and Nasdaq listing status.

Key Dates

Recommendation

The company exhibits significant revenue growth, largely driven by acquisitions, but this is overshadowed by widening net losses, deteriorating liquidity, and a critical Nasdaq delisting threat. The ongoing need for capital raises, coupled with the uncertainty of regaining Nasdaq compliance, presents substantial downside risk for investors. While the Teyame separation offers a potential future catalyst, the immediate financial health and listing status warrant a cautious approach.

Keywords

Healthcare IT, Customer Engagement Services, Software Services, Managed Services, AI, Cloud Services, Life Sciences, Business Combination